Targeting ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.

Yuxin LiuClifton C MoMonique A Hartley-Brown Adam S Sperling Shonali Midha Andrew J YeeGiada BianchiCatherine PiperAlice TattersallOmar NadeemJacob P LaubachPaul Gerard Richardson

Published in: Expert review of hematology (2024)

Emerging data suggest iberdomide and mezigdomide have promising activity, including in IMiD-resistant settings, and, pending phase 3 findings, may provide additional treatment options for patients with MM.

Keyphrases

multiple myeloma
electronic health record
cancer therapy
protein protein
drug delivery